Company ProfilePremium

Lippo China Resources Limited

Company Profile Analysis

Ticker: 0156.HK力寶華潤有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Lippo China Resources Limited - Company showcase

Year Founded & Workforce

1973

899 Employees

Lippo China Resources Limited logo

Lippo China Resources Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Lippo China Resources Limited Overview

Lippo China Resources is a Hong Kong-listed, Riady-family-controlled investment holding company. In practice it is a small Asian consumer-food operator wrapped around a portfolio of property, listed and unlisted securities, and two significant Singapore associates. Food businesses generate about 95% of consolidated revenue (HK$821m of HK$864m in FY2025). They comprise industrial bread manufacturing in Singapore and Malaysia and a café/restaurant estate in Hong Kong and Singapore operating under the Délifrance, Chatterbox Café, alfafa and Lippo Chiuchow names. Below the operating line, earnings are dominated by fair-value marks on a ~HK$0.5bn securities book, revaluation of Hong Kong commercial property, and equity-accounted results from Healthway Medical (40.76%; 130+ Singapore clinics) and SGX-listed TIH Limited (39.92%; private equity and fund management). The shares trade at roughly 0.45–0.5x book. After the 2024 Skye litigation settlement and the 2026 insurance recovery, the investment case rests on food-manufacturing growth in Malaysia, NAV realisation, and the governance direction of the Riady group.


Company's own description (latest annual results, FY2025)

In its FY2025 results announcement, the company defines seven reportable segments [S1]:

  1. Property investment: investments in letting and resale of properties.

  2. Treasury investment: money-market investments.

  3. Securities investment: securities held for trading and for long-term strategic purposes.

  4. Food businesses: mainly food manufacturing, plus food retail through café and bistro chains.

  5. Healthcare services: healthcare management services.

  6. Property management: property management services.

  7. Other: principally property development and sale, mineral exploration and extraction, and investment in a closed-end fund.

Management describes food businesses as the principal source of revenue, contributing 95% of FY2025 revenue (FY2024: 94%) [S1]. The food manufacturing operation sells various bread products in Singapore and Malaysia. The restaurant operation runs "Chatterbox Café", "Délifrance", "alfafa" and "Lippo Chiuchow Restaurant" in Hong Kong and "Délifrance" in Singapore [S1].

Revenue model

Revenue type (FY2025)HKD Mn% of totalNature
Food manufacturing (bread, Singapore & Malaysia)436.650.5%Product sales, B2B/B2C via retail channels; recognised at a point in time
Restaurant operation (HK & Singapore)382.744.3%Consumer F&B sales; recognised at a point in time
Management services (mainly property management)12.61.5%Service fees; recognised over time
Property rental income17.42.0%Operating-lease rentals
Dividend income10.01.2%Investment income
Interest income2.40.3%Investment income
Other2.80.3%Miscellaneous
Total864.5100%—

Source: FY2025 Final Results, Note 4 [S1].

Mix characterisation. About 95% of revenue comes from products (bread and F&B), about 3.5% from services and rental, and about 1.5% from investment income. There is no subscription or licensing revenue. Revenue understates the economic importance of the investment portfolio. Fair-value movements, revaluation, impairments and equity-accounted results sit outside revenue and have historically driven the bottom line. In FY2024, for example, a HK$386.5m litigation settlement and a HK$63.3m fair-value loss outweighed a HK$474.6m gross profit [S1].

Value-chain position, customers and end-markets

Food manufacturing: LCR is a mid-stream manufacturer. It buys flour and other inputs, operates baking lines and distributes packaged bread through retail and food-service channels in Singapore and, increasingly, Malaysia. Customer concentration is material: a single food-segment customer contributed HK$130.7m in FY2025 (15.1% of group revenue), up from HK$119.8m in FY2024, HK$114.7m in FY2023, HK$91.8m in FY2022 and HK$96.5m in FY2021 [S1][S2][S3]. The customer's identity is not publicly disclosed; it is most plausibly a large grocery retailer or distributor.

Food retail: LCR is downstream, consumer-facing, and exposed to Hong Kong discretionary spending, cross-border ("northbound") leakage, rent and labour costs.

Property: LCR is a small landlord of Hong Kong and Mainland commercial property, with rental income of HK$17.4m in FY2025 [S1].

Investments: LCR acts as a capital allocator, holding listed and unlisted equities, funds and debt. Its two principal associates are Healthway Medical (Singapore primary and specialist healthcare) and TIH Limited (Southeast Asian private equity and fund management) [S1].

End-markets: Singapore (54% of FY2025 revenue), Hong Kong (32%), Malaysia (12%), Mainland China (<1%) and other (1%) [S1].

Independent characterisation

LCR is best described as a holding-company discount vehicle whose consolidated P&L is a bakery-and-café business attached to a sizeable but non-core investment balance sheet. On a sum-of-the-parts view at 30 June 2026, associates (HK$912.7m), the FVPL portfolio (HK$492.3m), FVOCI equities (HK$31.2m), joint ventures (HK$41.8m) and investment properties (HK$580.8m) total about HK$2.06bn of carrying value [S4]. That is more than double the ~HK$0.94bn market capitalisation, before counting the food operations' fixed assets (HK$789.6m), and against borrowings of HK$916m [S4]. The operating engine is improving (analyst-derived adjusted EBITDA rose from HK$19m in FY2023 to HK$82m in FY2025). However, the business has not generated sustainable profit since FY2021 apart from one-offs. The discount reflects controlled-company governance, low free float (~17–27% depending on how the Tai holding is treated), illiquidity, and a record of value-destructive events such as the Skye/CS Mining litigation.

Strategy

Stated strategic themes (latest annual and interim reports)

LCR does not publish a formal multi-year strategy, investor-day material or numeric targets. Recurring management themes in the FY2023–H1 2026 filings are paraphrased below:

  1. Prudent capital management and cautious asset monitoring. Repeated in every prospects section: the group and its associates will manage businesses cautiously, monitor assets and investments, and manage capital prudently [S1][S2][S4].

  2. Innovation and reinvestment in food offerings. Management says it monitors market changes and innovates and reinvests in its products to meet customer preferences [S1][S4].

  3. Production capacity and efficiency. The Dec 2025 equipment purchase was described as value-adding to the existing business [S1].

  4. Malaysia expansion of food manufacturing, cited as a key revenue driver [S1][S4].

  5. Proactive but prudent portfolio management. Investments are run under an investment committee's terms of reference, seeking yield enhancement. Gains are realised (for example, Quantedge redemptions) to fund working capital [S1][S4].

  6. Balance-sheet repair for future distributions. The 2025 Capital Reduction was explicitly aimed at greater flexibility for corporate exercises and dividends [S1][S22].

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionTarget / statusSource
Litigation exit and insurance recoverySep 2024 – Feb 2026Settled Skye/CS Mining litigation for US$49.5m; recovered US$24.75m from corporate-liability insurersComplete[S1][S4]
Capital ReductionEffective 29 Jul 2025Share capital cut to HK$150m; HK$0.7bn offset against accumulated losses (accumulated losses were ~HK$636m at company level before the reduction)Complete[S1][S22]
Group restructuring – Lippo Limited privatisationMay–Sep 2025Parent privatised; LCR shares distributed to Lippo shareholders (cash alternative HK$0.564 per Lippo share)Complete 23 Sep 2025[S12]
Food manufacturing capacityDec 2025 – Q4 2026New commercial bread line; capital commitments HK$153–160mInstallation expected Q4 2026[S1][S4]
Malaysia market expansion2024–2026Malaysia food revenue up from HK$31.4m (FY2024) to HK$105.2m (FY2025)Ongoing[S1]
Restaurant estate rationalisationH1 2026Store closures in Hong KongOngoing[S4]
H2G Green stake build2025–2026Warrants exercised (+HK$13m), stake rose to 28.8%; board-nomination right obtained, making H2G an associate; diluted to 22.5% by placementOngoing[S1][S4]
Investment portfolio de-risking2022–2026Treasury and securities portfolio reduced from HK$1,947m (FY2021) to HK$731m (FY2025)Ongoing[S1][S3]

ESG commitments, cost programmes and medium-term guidance

Sustainability commitments: No quantified targets were found in retrieved sources.

Cost programmes: No formal programme with targets is disclosed. Legal and professional fees fell from HK$56.5m (FY2024) to HK$6.4m (FY2025) after the settlement [S1].

Medium-term financial targets or guidance: Not publicly disclosed. Management provides only qualitative macro outlooks, noting upward revisions to Hong Kong 2026 GDP forecasts (3.5–4.5%) and Singapore (4.5–5.5%) while flagging Middle East geopolitical risk [S4].

Products & Services

Food businesses — Food manufacturing

OfferingDescriptionMarket / target customerLaunch / statusPricing modelSource
Packaged bread products (Singapore)Industrial production of various bread products sold through retail and food-service channelsSingapore mass grocery consumers and institutional buyers; one customer = HK$130.7m in FY2025Long-established; continued growth in FY2025Wholesale/retail list pricing (not disclosed)[S1]
Packaged bread products (Malaysia)Expansion of the bread range into Malaysia; Malaysian share of food-manufacturing revenue rose from 9% (FY2024) to 24% (FY2025)Malaysian grocery channelExpansion accelerated 2024–2026—[S1]
New products (unspecified)Management cites "launch of new products" as a growth driver in FY2025 and H1 2026Singapore and Malaysia2025–2026—[S1][S4]
Historical brand portfolio (context)Auric's 2015 annual report shows Sunshine and Top One breads made at Auric's own facilities, the Buttercup spread, Sunshine frozen pizza and Gourmet delicatessen brands, plus a Malaysian unit, Auric Pacific Food Processing Sdn. Bhd.Singapore and MalaysiaHistorical (2015)—[S14]
New commercial production lineOne line of commercial food-manufacturing equipment agreed in Dec 2025; installation expected in Q4 2026Capacity and efficiencyCommissioning Q4 2026Capex (part of HK$153–160m commitments)[S1][S4]

Food businesses — Food retail (restaurants and cafés)

BrandFormatGeographyNotesSource
DélifranceFrench-style café-bakery and bistroHong Kong and SingaporeOwned via Délifrance Asia (acquired 2007). Rebranding with "Délifrance Bistro" concept launched in Hong Kong in March 2023[S1][S2][S3][S14]
Chatterbox CaféCasual dining (Singapore-style cuisine)Hong KongTwo new outlets opened in 2023[S1][S2]
Chatterbox ExpressExpress formatHong KongListed in FY2022–FY2023 filings; not listed among FY2025 or H1 2026 brands, implying discontinuation or rebranding (not explicitly disclosed)[S2][S3][S1]
alfafaCafé/casual diningHong KongOngoing[S1]
Lippo Chiuchow Restaurant (力寶軒)Chiu Chow (Teochew) Chinese restaurantHong KongOngoing[S1][S4]

Outlet counts, average ticket, same-store sales and menu pricing are not publicly disclosed. H1 2026 disclosures note that "some stores were closed" in Hong Kong [S4].

Property investment and property management

OfferingDescriptionSource
Commercial investment propertiesPortfolio mainly of commercial properties in Hong Kong and Mainland China; carrying value HK$566.9m (Dec 2025), HK$580.8m (Jun 2026). Individual property names and GFA not disclosed in the retrieved filings[S1][S4]
Owner-occupied office buildingsFixed assets including HQ-type offices in Hong Kong; impaired HK$79.9m (FY2024) and HK$40.5m (FY2025)[S1]
Property management servicesFee-based services in Hong Kong (HK$10.3m) and Mainland China (HK$2.0m) in FY2025[S1]

Treasury and securities investments (principal positions)

HoldingTypeCarrying value (latest)DescriptionSource
GSH Corporation LimitedListed equity (SGX Mainboard), FVPLHK$80.1m (Jun 2026); HK$83.3m (Dec 2025)Malaysian and Mainland property and hospitality: Sutera Harbour Resort in Kota Kinabalu (two five-star hotels, 104-berth marina, 27-hole golf course), Sutera@Mantanani Resort, and a 200-room Chongqing hotel. Placed ~S$112m of new shares in 2025 and earmarked ~S$35m for digital-asset mining[S1][S4]
Amasia CIV T, L.P.Unlisted single-asset fund, FVPLHK$56.4m (Jun 2026)Holds Dialpad, Inc. (AI-powered communications and contact-centre platform). US$2m invested in 2015[S1][S4]
Quantedge Global FundUnlisted multi-asset fund, FVPLHK$50.1m (Jun 2026)Partial redemptions used for working capital (HK$9m in FY2025, HK$3m in H1 2026)[S1][S4]
Other FVPL securitiesEquities, debt, fundsHK$305.7m (Jun 2026)No single item above 7% of FVPL[S4]
GenieBiome HoldingsUnlisted biotech, FVOCIHK$23m (Jun 2026)Hong Kong microbiome precision-health company founded by university clinician-scientists; pays dividends[S1][S4]
H2G Green LimitedSGX Catalist; associate from H1 2026HK$33m (Jun 2026); ~22.5% stakeLNG cylinder supply for last-mile clean-energy distribution. Sold its biomass-to-fuel subsidiary in July 2026 to focus on LNG[S1][S4]

Healthcare services (associate)

OfferingDescriptionSource
Healthway Medical Group (40.76%)Network of 130+ clinics, primarily in Singapore: GP and family medicine, health screening, adult specialists, baby and child specialists, dental, a day-surgery centre and allied health. Participant in the national Healthier SG programme (65 clinics enrolled as of FY2023). Brands and acquisitions include Nobel specialist clinics, Straits Podiatry, Ten Surgery Group, Amazing Speech Therapy, HeadStart for Life, TeleHope Speech Therapy and UROHEALTH (urology). In July 2026, proposed acquisition of the Bridgepoint Health network of 16 primary-care clinics[S1][S2][S3][S4]

Other

OfferingDescriptionSource
TIH Limited (39.92%)SGX-listed investment business (special situations, secondary portfolios, private credit, long-term private equity) and fund management via TIH Investment Management Pte. Ltd., which holds an MAS capital markets services licence[S1][S3]
Mineral exploration and extractionResidual activity within "Other". Capital expenditure definitions include exploration and evaluation assets; specific projects not disclosed[S1]
Closed-end fund investmentWithin "Other"; fund identity not disclosed[S1]
Property development and saleWithin "Other"; no active projects disclosed[S1]

Financial Narrative

Sources: FY2022 Final Results (FY2021–22) [S3]; FY2023 Final Results [S2]; FY2025 Final Results (FY2024–25) [S1]. Currency HK$ million unless stated. FY2025 figures come from the preliminary announcement agreed by EY. The H1 2026 interim confirms the FY2025 statements were subsequently audited with an unqualified opinion [S4].

Income statement

Note: Adjusted EBITDA is post-HKFRS 16 (it adds back right-of-use depreciation). It excludes fair-value, impairment, litigation and associate items. FY2024 other operating expenses include HK$56.5m of legal and professional fees linked to the litigation [S1].

Margins and growth

Revenue CAGR (analyst-derived): FY2021–FY2025 4-year CAGR ≈ 7.4%; FY2022–FY2025 3-year CAGR ≈ 12.5%.

Gross margin is structurally high for a food business because, under LCR's presentation, cost of sales captures mainly cost of inventories sold (HK$330.7m in FY2025). Restaurant labour, rent (via right-of-use depreciation) and utilities sit in administrative and other operating expenses [S1]. For that reason the gross margin should not be compared directly with HK fast-food peers, which report gross margins of 8–10% after including staff and rent in cost of sales.

Per-share data (restated for the 10:1 consolidation of June 2023)

FY2021 EPS was reported as HK0.53 cents pre-consolidation; FY2021 final dividend HK0.45 cents and FY2022 interim HK0.35 cents pre-consolidation [S3]. Diluted EPS equals basic; there are no dilutive instruments [S1].

Balance sheet

Sources: [S1][S2][S3]. Within borrowings, bank loans were HK$765m and unsecured loans from holding companies HK$187m at Dec 2025 (Dec 2024: HK$796m and HK$170m) [S1].

Interim balance sheet (30 June 2026) [S4]: total assets HK$3,483.4m; total liabilities HK$1,242.7m; cash HK$249.4m plus HK$13.5m restricted; borrowings HK$916.1m (current HK$137.5m, non-current HK$778.5m; bank loans HK$784m, related-party loans HK$132m); equity attributable HK$2,015.5m; NCI HK$225.2m; gearing ratio 42.1%; current ratio 1.5.

Cash flow and capital deployment

The FY2024 litigation payment of US$49.5m (HK$386.5m) was a major cash outflow, funded partly by higher borrowings: total borrowings rose from HK$644.8m to HK$965.9m and related-party loans of HK$170m appeared [S1][S2]. The FY2025 HK$77.1m insurance advance and the 2026 balance of HK$115.6m reverse about half of that outflow [S4]. LCR made no repurchases in FY2022–FY2025 or H1 2026 [S1][S2][S3][S4].

Ratios

All ratios are analyst-derived from reported balances [S1][S2][S3]. The company-defined gearing ratio is borrowings net of NCI divided by attributable equity, as reported. Working-capital days use trade debtors and creditors from the ageing notes against total revenue and cost of inventories sold. Net debt/EBITDA is not meaningful (blank) where adjusted EBITDA was negative.

Half-year comparison: notes and sources

Sources: H1 2025 Interim Results (H1 2024–25) [S6]; H1 2026 Interim Results [S4].

Trend commentary

Revenue. Revenue fell in FY2022 (-6.3%) as Hong Kong dine-in restrictions and Malaysian start-up problems hit food sales [S3]. It rebounded in FY2023 (+21.7%) when Hong Kong reopened [S2], grew modestly in FY2024 (+4.9%) and accelerated in FY2025 (+11.5%) on manufacturing [S1]. The growth mix has shifted decisively. Restaurants grew only 2% in FY2025 and fell 13% in H1 2026, while manufacturing grew 25% and then 21% [S1][S4]. Malaysia went from HK$1.0m of revenue in FY2021 to HK$106.8m in FY2025 [S1][S3].

Profitability. Gross margin widened by about 10 points from FY2021 to FY2025, consistent with mix shift and input-cost management. Operating losses narrowed from HK$198m to HK$44m. Even so, administrative costs (HK$436.6m) still consumed 82% of gross profit in FY2025. Staff costs rose 12% in FY2025 to HK$334m with headcount up 7% [S1]. Adjusted EBITDA inflected positive in FY2023 and reached HK$82m in FY2025. H1 2026 adjusted EBITDA of about HK$30m (analyst-derived) was roughly flat on H1 2025.

Below-the-line volatility. FVPL marks swung from +HK$226m (FY2021) to -HK$104m (FY2022). The portfolio was then deliberately shrunk: FVPL assets fell from HK$1,129m to HK$490m. Hong Kong commercial property has been a persistent drag, with cumulative FY2021–FY2025 fair-value losses of HK$112.7m plus HK$120.4m of office impairments. The FY2024 loss of HK$683.7m was dominated by the HK$386.5m litigation settlement. The FY2025 headline loss of HK$61.3m was flattered by a HK$104.2m reversal of prior-year tax over-provision, which collapsed tax payable from HK$119.2m to HK$20.6m [S1]. Without it, the FY2025 pre-tax loss was HK$153.5m.

Balance sheet. Attributable equity fell 39% from HK$3,078m (FY2021) to HK$1,865m (FY2025). Net debt rose from HK$205m to HK$718m while cash fell from HK$860m (including time deposits) to HK$240m. The group is now structurally dependent on secured bank financing plus HK$132–187m of unsecured loans from controlling-shareholder entities [S1][S4]. Refinancing in 2023 cut current-maturity exposure from 64% to 22% of borrowings [S2]. Short-term maturities were 13% at Dec 2025 and 15% at Jun 2026 [S1][S4]. H1 2026 profit and the insurance cash cut gearing to 42.1% from 48.1% [S4].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LevelEntityInterestNotes

Ultimate controller

Dr. Stephen Riady and family

—

Via Lippo Capital group [S11][S13]

Shareholder

Skyscraper Realty Limited (subsidiary of Lippo Limited, privatised Sept 2025)

48.45% of LCR

[S12]

Shareholder

Lippo Capital Limited

24.76% of LCR

[S12]

Shareholder

Mr. Stephen Tai Tak Fung

9.30% of LCR (as at 31 Mar 2026)

[S11]

Subsidiary group

Auric Pacific Group and subsidiaries (food manufacturing, Délifrance Asia)

—

NCI of HK$231m at Dec 2025 indicates partly-owned subsidiaries [S1][S14]

Associate

Healthway Medical Corporation Limited

40.76%

Healthcare services segment [S1]

Associate

TIH Limited (SGX Mainboard)

39.92%

"Other" segment [S1]

Associate (from H1 2026)

H2G Green Limited (SGX Catalist)

~22.5%

Reclassified from FVOCI after LCR obtained a board-nomination right [S4]

Joint venture

Unnamed JV in securities investment segment

—

Impaired by HK$40.7m in FY2025 [S1]

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Property investment external revenue (HKD Mn)

18.517.218.717.017.4

Treasury investment external revenue (HKD Mn)

2.43.65.92.80.5

Securities investment external revenue (HKD Mn)

16.811.611.811.311.7

Food businesses external revenue (HKD Mn)

596.5560.3687.3727.8821.2

Healthcare services external revenue (HKD Mn)

00000

Property management external revenue (HKD Mn)

—12.912.512.512.3

Other external revenue (HKD Mn; FY2021 includes property management)

14.41.93.33.91.4

Total revenue (HKD Mn)

648.5607.4739.4775.3864.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Property investment result (HKD Mn)

-7.1-23.0-25.0-118.3-59.8

Treasury investment result (HKD Mn)

2.43.65.92.80.5

Securities investment result (HKD Mn)

212.7-100.826.0-57.8-27.2

Food businesses result (HKD Mn)

-66.6-110.7-55.2-34.816.1

Healthcare services result (HKD Mn)

-1.9-1.8-2.7-0.50

Property management result (HKD Mn)

—9.19.99.89.7

Other result (HKD Mn)

-9.1-7.8-5.14.3-0.8

Unallocated corporate expenses (HKD Mn; FY2024 includes litigation settlement)

-123.7-99.8-95.2-505.9-72.0

Share of associates – Healthway (HKD Mn)

25.429.27.7-0.53.4

Share of associates – TIH/other (HKD Mn)

24.810.8-12.242.320.0

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2023FY2024FY2025

Food segment margin (% of food revenue)

-8.0-4.82.0

Food revenue YoY growth (%)

22.75.912.8

Food share of group revenue (%)

92.993.995.0

Property management margin (% of total segment revenue)

75.875.075.8

Property investment total segment revenue incl. inter-segment (HKD Mn)

22.721.421.8

Property investment net FV loss on investment properties (HKD Mn)

-25.7-37.2-20.9

Property investment impairment on owner-occupied offices (HKD Mn)

0-79.9-40.5

Revenue by Segment — Food manufacturing revenue

MetricFY2021FY2022FY2023FY2024FY2025

Food manufacturing revenue (HKD Mn)

285.7266.5324.5348.2436.6

Restaurant operation revenue (HKD Mn)

307.4291.1359.9376.1382.7

Results by Segment (Half-Yearly)

MetricH1 2025H1 2026

Food businesses revenue (HKD Mn)

392.3411.3

Food manufacturing revenue (HKD Mn)

202.9245.6

Restaurant revenue (HKD Mn)

187.8164.3

Food segment result (HKD Mn)

-2.5-10.7

Property investment result (HKD Mn)

-8.27.4

Securities investment result (HKD Mn)

5.88.3

Property management result (HKD Mn)

4.95.2

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

648.5607.4739.4775.3864.5

Cost of sales (HKD Mn)

-316.6-290.9-309.3-300.7-332.6

Gross profit (HKD Mn)

332.0316.5430.1474.6531.8

Other income – government grants etc. (HKD Mn)

12.115.91.700

Administrative expenses (HKD Mn)

-392.4-379.2-399.6-409.2-436.6

Other operating expenses (HKD Mn)

-149.6-138.2-146.2-180.9-138.9

Operating income, analyst-derived: GP + other income – admin – other opex (HKD Mn)

-197.9-185.0-114.0-115.5-43.7

Net FV gain/(loss) on FVPL instruments (HKD Mn)

226.2-104.319.9-63.34.1

Net FV loss on investment properties (HKD Mn)

-6.8-22.1-25.7-37.2-20.9

Impairment of fixed assets, separately presented (HKD Mn)

000-79.9-40.5

Other losses – net (HKD Mn)

-3.1-8.0-9.8-8.7-23.3

Litigation settlement (HKD Mn)

000-386.50

Finance costs (HKD Mn)

-30.2-40.0-52.3-56.7-52.6

Share of associates (HKD Mn)

50.240.0-4.541.823.4

Share of joint ventures (HKD Mn)

-0.4-0.40.3-0.50

Profit/(loss) before tax (HKD Mn)

37.9-320.0-186.0-706.4-153.5

Income tax credit/(charge) (HKD Mn)

1.13.51.2-2.397.9

Profit/(loss) for the year (HKD Mn)

39.0-316.5-184.8-708.8-55.6

Attributable to non-controlling interests (HKD Mn)

-9.7-38.6-38.3-25.15.7

Net income attributable to shareholders (HKD Mn)

48.7-277.9-146.4-683.7-61.3

Total comprehensive income attributable to shareholders (HKD Mn)

-5.5-329.5-177.6-719.0-0.9

Depreciation – fixed assets + right-of-use (HKD Mn)

114.9124.2133.2134.3126.0

Adjusted EBITDA, analyst-derived: operating income + D&A (HKD Mn)

-83.0-60.819.218.882.3

Reported-basis EBITDA, analyst-derived: PBT + finance costs + D&A (HKD Mn)

183.0-155.8-0.5-515.425.1

Staff costs (HKD Mn)

315283290297334

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue YoY growth (%)

—-6.321.74.911.5

Gross margin (%)

51.252.158.261.261.5

Operating margin, analyst-derived (%)

-30.5-30.5-15.4-14.9-5.1

Adjusted EBITDA margin (%)

-12.8-10.02.62.49.5

Pre-tax margin (%)

5.8-52.7-25.2-91.1-17.8

Net margin attributable (%)

7.5-45.8-19.8-88.2-7.1

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

EPS basic and diluted (HKD)

0.053-0.30-0.16-0.74-0.07

Dividend per share (HK$, restated)

0.0450.035000

Total dividends declared (HKD Mn)

41.332.2000

NAV per share attributable (HKD)

3.352.912.721.932.03

Weighted average shares (M, restated)

918.7918.7918.7918.7918.7

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

5,004.74,392.03,976.33,504.03,464.0

Non-current assets (HKD Mn)

3,530.73,293.83,185.22,945.42,898.5

Current assets (HKD Mn)

1,474.11,098.3791.1558.6565.6

Cash and cash equivalents (HKD Mn)

783.3652.8301.6283.2233.9

Time deposits >3 months and restricted cash (HKD Mn)

76.40006.5

Fixed assets (HKD Mn)

1,052.71,003.2960.5835.3794.6

Investment properties (HKD Mn)

685.7644.4617.1575.5566.9

Interests in associates (HKD Mn)

784.9821.9819.6823.7892.0

Interests in joint ventures (HKD Mn)

75.776.978.678.341.4

Financial assets at FVPL – current + non-current (HKD Mn)

1,129.4784.6749.3492.9490.1

Financial assets at FVOCI (HKD Mn)

78.572.649.346.368.1

Goodwill and intangibles (HKD Mn)

21.021.021.021.021.0

Short-term bank and other borrowings (HKD Mn)

337.1550.9141.8191.6123.7

Long-term bank and other borrowings (HKD Mn)

651.4312.5503.0774.3828.4

Total borrowings (HKD Mn)

988.6863.4644.8965.9952.1

Lease liabilities (HKD Mn)

166.1165.4172.8161.8131.9

Net debt excl. leases: borrowings – cash (HKD Mn)

205.3210.6343.2682.7718.2

Total liabilities (HKD Mn)

1,542.81,369.01,151.81,431.11,367.8

Tax payable (HKD Mn)

117.4116.5116.8119.220.6

Equity attributable to shareholders (HKD Mn)

3,078.32,673.22,495.81,776.81,864.9

Non-controlling interests (HKD Mn)

383.6349.8328.8296.1231.4

Total equity (HKD Mn)

3,462.03,023.02,824.52,072.92,096.2

Working capital – net current assets (HKD Mn)

731.3179.8291.829.1118.6

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Capital expenditure – segment + unallocated (HKD Mn)

40.337.446.631.627.8

Dividends paid in cash, analyst-derived from declarations (HKD Mn)

—73.5000

Share buybacks (HKD Mn)

—0000

Adjusted EBITDA minus capex, FCF proxy, analyst-derived (HKD Mn)

-123.3-98.2-27.4-12.854.5

Capital commitments at year-end (HKD Mn)

1141218884160

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE on average attributable equity (%; FY2021 on year-end equity)

1.6-9.7-5.7-32.0-3.4

ROA on average total assets (%; FY2021 on year-end assets)

0.8-6.7-4.4-19.0-1.6

ROIC: operating income / (total equity + borrowings) (%)

-4.4-4.8-3.3-3.8-1.4

Current ratio (x)

1.981.201.581.051.27

Total borrowings / total equity (x)

0.290.290.230.470.45

Company-defined gearing ratio (%)

28.428.624.853.048.1

Net debt / adjusted EBITDA (x)

——17.936.38.7

Adjusted EBITDA / finance costs (x)

-2.75-1.520.370.331.56

EBIT (PBT + finance costs) / finance costs (x)

2.3-7.0-2.6-11.5-1.9

Asset turnover: revenue / average total assets (x)

0.130.130.180.210.25

Inventory days

21.731.828.530.533.6

Trade receivable days

28.136.131.634.340.4

Trade payable days

44.857.351.954.348.2

Cash conversion cycle (days)

5.010.68.210.525.8

Income Statement and Per-Share Data

MetricH1 2024H1 2025H1 2026

Revenue (HKD Mn)

374.1412.1434.4

Gross profit (HKD Mn)

231.5256.7255.4

Administrative expenses (HKD Mn)

-210.6-217.0-204.8

Other operating expenses (HKD Mn)

-94.9-75.4-79.6

Insurance recovery income (HKD Mn)

00192.6

Finance costs (HKD Mn)

-25.6-27.8-25.7

Profit/(loss) for the period (HKD Mn)

-150.9-84.2134.3

Profit/(loss) attributable to shareholders (HKD Mn)

-137.3-80.3142.1

EPS (HKD)

—-0.090.15

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

Hong Kong revenue (HKD Mn)

238.2196.3255.3265.7275.3

Mainland China revenue (HKD Mn)

8.59.17.55.96.5

Singapore revenue (HKD Mn)

392.0391.6452.9456.6465.9

Malaysia revenue (HKD Mn)

1.02.510.532.8106.8

Other revenue (HKD Mn)

8.97.813.214.49.9

Region Margins & Growth (%) and Revenue by Region (%)

MetricFY2023FY2024FY2025

Hong Kong YoY growth (%)

30.04.13.6

Mainland China YoY growth (%)

-17.9-21.010.2

Singapore YoY growth (%)

15.60.82.0

Malaysia YoY growth (%)

316.4211.4226.1

Other YoY growth (%)

69.98.5-31.2

Singapore share of revenue (%)

61.358.953.9

Hong Kong share of revenue (%)

34.534.331.8

Malaysia share of revenue (%)

1.44.212.4

Revenue by Region (FY2023–FY2025)

Segment × regionFY2023FY2024FY2025

Food – Hong Kong (HKD Mn)

227.5240.7251.2

Food – Singapore (HKD Mn)

447.3452.2462.9

Food – Malaysia (HKD Mn)

9.631.4105.2

Property management – Hong Kong (HKD Mn)

10.410.510.3

Property management – Mainland China (HKD Mn)

2.01.92.0

Locations

LocationFY2023FY2024FY2025

Hong Kong non-current assets (HKD Mn)

1,118.9974.0870.9

Mainland China non-current assets (HKD Mn)

150.8145.1144.7

Singapore non-current assets (HKD Mn)

948.4946.0999.7

Malaysia non-current assets (HKD Mn)

311.9290.8324.2

Other non-current assets (HKD Mn)

131.3131.8102.5

Observation Details

ObservationPrice (HKD)Market cap (HKD Mn)

~Mar 2025 (FY2024 board-meeting notice)

—854.4

~Apr 2025 (share-charge release)

—808.4

~29 May 2025 (trading resumption)

—753.3

~Sep 2025 (distribution effective)

—771.7

~Oct 2025 (shareholding update)

—836.0

Stockopedia (date not stated; 1-year move +21.33%)

0.91836.0

12 Jun 2026 (Google Finance)

1.02937.1

52-week range at 12 Jun 2026

0.66 – 1.13

—

Valuation Multiples

MultipleLCRBasis

Price / book (attributable NAV)

0.46x

NAV HK$2,015.5m at 30 Jun 2026 [S4]

Price / book (FY2025 NAV)

0.50x

HK$1,864.9m [S1]

P/E (TTM to Jun 2026)

~5.8x

TTM profit attributable ≈ HK$161m (FY2025 -61.3 + H1 2026 142.1 – H1 2025 -80.3); includes HK$192.6m one-off insurance income

EV / Sales (TTM revenue ≈ HK$886.8m)

~2.0x

EV ≈ HK$1,815m (mkt cap 937 + borrowings 916 + NCI 225 – cash 263), excluding leases

EV / adjusted EBITDA (TTM ≈ HK$84.5m)

~23x (lease-inclusive EV ≈ HK$1,935m)

Distorted: EV includes ~HK$2bn of non-EBITDA-generating investments and associates

Dividend yield

0%

No dividend since 2022

Per-Share Data and Dividends & Capital Returns — Interim DPS

MetricFY2021FY2022FY2023FY2024FY2025

Interim DPS (HK cents, pre-consolidation basis)

00.35000

Final DPS (HK cents, pre-consolidation basis)

0.450000

Total dividends declared (HKD Mn)

41.332.2000

Debt Maturity Profile

Maturity bucket31 Dec 2025 (HKD Mn)30 Jun 2026 (HKD Mn)

Within one year / on demand

123.7 (13%)

137.5 (15%)

Beyond one year

828.4 (87%)

778.5 (85%)

Total bank and other borrowings

952.1916.1

Analyst Conclusions

Management guidance

There is no quantitative guidance. In the H1 2026 prospects section, management is cautiously optimistic on Hong Kong (2026 GDP forecast raised to 3.5–4.5%) and Singapore (raised to 4.5–5.5%). It expects Mainland growth to slow in H2 2026 and flags materially higher downside risks from the Middle East conflict. The group commits to cautious management of businesses and assets and prudent capital management [S4]. The new production line is expected to be installed in Q4 2026 [S4].

Consensus

Not available. There is one third-party "Hold" with a HK$1.00 target (TipRanks) [S12].

Bull case

  1. Manufacturing compounding. Manufacturing revenue grew 25% (FY2025) and 21% (H1 2026). With Q4 2026 capacity added, FY2026–27 group adjusted EBITDA could plausibly exceed the FY2025 level of HK$82m, turning operating income positive for the first time in the period reviewed [S1][S4].

  2. Deep value with a catalyst path. At ~0.46x NAV, after the Capital Reduction and with gearing down to 42.1%, the board has both the reserves and the cash (insurance proceeds) to resume dividends. A resumption would re-rate a stock trading below its investment and associate portfolio value alone [S1][S4].

  3. Cleaner group structure. The Lippo Limited privatisation and the direct Riady holding through Lippo Capital simplify ownership. The arrival of a 9.30% independent holder (Tai Tak Fung) adds a potential minority voice or catalyst [S11][S12].

Bear case

  1. No core profitability. Excluding one-offs, LCR lost money at the operating level in every year from FY2021 to FY2025. Hong Kong retail is deteriorating (-13% in H1 2026), and a HK$437m overhead base consumes most of the gross profit [S1][S4].

  2. Volatile, opaque NAV. About half of assets are associates, funds and illiquid holdings. Large historical marks (FY2022 FVPL loss of HK$104m) and impairments (HK$120m on offices, HK$40.7m on a JV) mean book value can erode quickly. Attributable equity fell 39% in four years [S1][S3].

  3. Governance and capital-allocation record. The Skye/CS Mining episode cost a net ~US$24.75m after insurance, plus years of legal fees. Related-party funding and interlocking boards keep minority shareholders dependent on the controller's priorities. The holding-company discount may prove permanent [S1][S4].

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhy it matters
Commissioning of the new production lineQ4 2026Capacity and unit-cost benefits for Malaysian growth
FY2026 results and dividend decision~Mar 2027First full year post-Capital Reduction; dividend resumption test
Hong Kong restaurant estate actionsOngoingClosures versus refits; segment breakeven
Malaysian revenue trajectory and QAF/Gardenia competitive responseOngoingDurability of the growth engine
Healthway's Bridgepoint acquisition completionH2 2026 – 2027Associate earnings uplift
Hong Kong commercial property valuationsDec 2026 valuationRevaluation gains or impairment reversals
Gearing and related-party loan repaymentEach reporting dateBalance-sheet independence
Any corporate action by the Riady group (e.g., privatisation offer)UnpredictableTypical exit route for Lippo-group minorities; currently unconfirmed
Stephen Tai Tak Fung stake changesOngoingPotential activism or block trade

Analyst verdict

Lippo China Resources has reached an inflection in balance-sheet terms, but not yet in earnings quality. Since 2024 it has removed its single largest overhang, the Skye/CS Mining litigation, and clawed back half the settlement from insurers. It has also cut gearing from 53% to 42%, reset its share capital to permit distributions, and completed a parent-level restructuring that leaves the Riady family holding about 73% directly and through Skyscraper. At HK$1.02, the shares trade at roughly 0.46x attributable NAV of HK$2.2 per share. Associates, securities and investment properties alone carry about HK$2.06bn, more than twice the market capitalisation.

The operating story is genuinely improving but narrow. Bread manufacturing, especially in Malaysia, is growing more than 20% a year and moved the food segment into profit in FY2025. The Hong Kong café estate, however, is shrinking, and group overhead still absorbs more than 80% of gross profit. Without the HK$104m tax write-back in FY2025 and the HK$193m insurance recovery in H1 2026, the group would have reported losses in both periods. Adjusted EBITDA of about HK$82m does not cover HK$53m of finance costs plus maintenance capex with much room to spare.

The investment case is therefore a NAV-realisation and capital-return thesis rather than a growth compounder. The decisive tests over the next 12 months are threefold: whether the new production line lifts manufacturing margins; whether management uses the newly created distributable reserves to resume dividends; and whether Hong Kong retail can stabilise. Absent a dividend or a controller-led corporate action, the holding-company discount is likely to persist, given low liquidity, no sell-side coverage and a history of value leakage. The rating is Neutral / speculative value. The risk-reward is asymmetric for patient, governance-tolerant investors, but would justify an upgrade only on evidence of recurring profitability or explicit capital returns.


SOURCES REGISTER

S1: LCR Final Results for the year ended 31 Dec 2025 (incl. FY2024 comparatives) — 31 Mar 2026 — https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033103919.pdf

S2: LCR Final Results for the year ended 31 Dec 2023 (incl. FY2022 comparatives) — 27 Mar 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0327/2024032702309.pdf

S2b: LCR Date of Board Meeting — 15 Mar 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0315/2024031501343.pdf

S2c: LCR 2023 Annual Report — 29 Apr 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0429/2024042903663.pdf

S3: LCR Final Results for the year ended 31 Dec 2022 (incl. FY2021 comparatives) — 30 Mar 2023 — https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0330/2023033004258.pdf

S4: LCR Interim Results for six months ended 30 Jun 2026 (Chinese version) — 28 Aug 2026 — https://pdf.dfcfw.com/pdf/H2_AN202608281828642708_1.pdf

S5: LCR Positive Profit Alert (H1 2026) — 24 Aug 2026 — https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401119.pdf

S6: LCR Interim Results / Interim Report for six months ended 30 Jun 2025 — 28 Aug 2025 / 29 Sep 2025 — https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0828/2025082801882.pdf ; https://www.hkexnews.hk/listedco/listconews/sehk/2025/0929/2025092901062.pdf

S6b: News brief on H1 2025 interim report (Reuters via Tiger Brokers) — Sep 2025 — https://www.itiger.com/news/2571838300

S6c: LCR Interim Results H1 2024 — 27 Aug 2024 — https://newsfile.moomoo.com/public/NN-PersistNoticeAttachment/7781/20240827/11338240-0.PDF

S7: LCR Retirement of INED and change in board committees — 31 Mar 2026 — https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033102533.pdf

S8: LCR Re-designation of ED; appointment of ED and CEO — 6 Jun 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0606/2024060601887.pdf

S9: LCR List of Directors and their roles and functions — 7 Jun 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0607/2024060701020.pdf

S10: LCR Change of INED — 12 Dec 2022 — https://www1.hkexnews.hk/listedco/listconews/sehk/2022/1212/2022121200933.pdf

S11: ET Net company information (major shareholders, bankers, board) — Apr 2026 — https://www.etnet.com.hk/www/eng/stocks/realtime/quote_ci_brief.php?code=156

S12: TipRanks announcement summaries (Lippo privatisation, distribution in specie, shareholding update) — 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-updates-shareholding-structure ; https://www.tipranks.com/news/company-announcements/lippo-limited-announces-privatization-and-delisting-plan

S13: Wikipedia – Lippo Limited (group history) — Accessed Oct 2026 — https://en.wikipedia.org/wiki/Lippo_Limited

S14: Auric Pacific / Délifrance / DKSH / BreadTalk deal sources — 2007–2019 — https://en.wikipedia.org/wiki/D%C3%A9lifrance ; https://www.marktpuls.ch/artikel/permalink/318776 ; https://testing.dev.theedgesingapore.com/capital/ma/breadtalk-buying-over-food-junction-80-mil-auric-pacific ; https://www.hkexnews.hk/listedco/listconews/sehk/2016/0407/LTN201604071281.pdf

S15: Yahoo Finance company profile (key executives, compensation FY2023) — Accessed Oct 2026 — https://nz.finance.yahoo.com/quote/0156.HK/profile

S16: Google Finance / Simply Wall St / Stockopedia quotes — Jun 2026 — https://www.google.com/finance/quote/0156:HKG ; https://simplywall.st/stock/sehk/156 ; https://stockopedia.com/share-prices/lippo-china-resources-HKG:156

S17: Peer filings: QAF Annual Report FY2025; Café de Coral FY2025/26 results; Fairwood FY2025/26 results — Feb–Jun 2026 — https://links.sgx.com/1.0.0/corporate-announcements/S6G3FR58FAT6SQKC/880751_QAF%20Annual%20Report%20FY2025.pdf ; https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0615/2026061500255.pdf ; https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000667.pdf

S18: MarketScreener – King Fai Tsui insider profile (LCR appointment 8 Jun 2026) — Jun 2026 — https://in.marketscreener.com/insider/KING-FAI-TSUI-A07E9W/

S19: News report on FY2025 profit warning (Tiger Brokers) — Mar 2026 — https://www.itiger.com/news/1110788779

S20: LCR Profit Warning FY2023 — 22 Mar 2024 — https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0322/2024032200911.pdf

S21: LCR 2005 Annual Report (corporate information); 2002 Annual Report — 2006 / 2003 — https://www.hkexnews.hk/listedco/listconews/sehk/2006/0503/0156/EWF103.pdf ; https://www.hkexnews.hk/listedco/listconews/sehk/2003/0506/156/EWF106.pdf

S22: TipRanks summary – proposed Capital Reduction — 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-announces-proposed-capital-reduction-to-address-accumulated-losses

S23: TipRanks summary – release of share charge — Apr 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-announces-release-of-share-charge

S24: TipRanks summaries – FY2024 board meeting; 2025 AGM notice — Mar–May 2025 — https://www.tipranks.com/news/company-announcements/lippo-china-resources-schedules-board-meeting-to-approve-2024-financial-results ; https://www.tipranks.com/news/company-announcements/lippo-china-resources-limited-announces-annual-general-meeting

End of dossier.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / appointmentAge / bornPrior and concurrent roles

Dr. Stephen Riady

Executive Director, Chairman

Long-serving; Deputy Chairman, MD and CEO in 2005

Born 1960 (aggregator)

Chairman of Lippo Limited and Hongkong Chinese Limited; director of Lippo Capital entities; principal of the Riady family interests controlling LCR

Mr. John Luen Wai Lee, BBS, JP

Executive Director, Deputy Chairman

Director since at least 2002; CEO until 7 Jun 2024, then Deputy Chairman

Aged 75 in Jun 2024 (born 1949)

Formerly MD and CEO of Lippo Limited and CEO of HKC; re-designated Deputy Chairman of Lippo in Jun 2024; Certified Public Accountant

Mr. Davy Kwok Fai Lee

Executive Director, Chief Executive Officer

Since 7 Jun 2024 (initial two-year term)

Born 1959 (aggregator)

Concurrently ED and CEO of Lippo Limited and HKC from 7 Jun 2024; director and Secretary of Skyscraper Realty; Secretary of Lippo Capital Limited, Lippo Capital Holdings and Lippo Capital Group

Mr. James Siu Lung Lee

Executive Director

Long-serving

Born 1970 (aggregator)

Described by aggregators as EVP Business Development

Mr. Brian Riady

Executive Director

—

Born 1990 (aggregator)

—

Mr. Leon Nim Leung Chan

Non-executive Director

On board since at least 2005

—

Member of Audit, Remuneration and Nomination Committees

Mr. Edwin Neo

Independent NED

INED since at least 2005

—

Chairman of Remuneration and Nomination Committees (2024 list); Audit Committee member

Ms. Min Yen Goh

Independent NED

Since 30 Dec 2022

—

Also INED of Lippo Limited and HKC; Remuneration and Nomination Committee member

Mr. King Fai Tsui

Independent NED; Audit Committee Chairman

Re-appointed 8 Jun 2026 (previously INED Sep 2004 – Dec 2022)

~76 (aggregator)

INED of Lippo Limited, HKC and Newton Resources; former INED of China Aoyuan and Vinda International

“—” = not publicly disclosed.

Executive Leadership Team

NameTitle

Mr. Davy Kwok Fai Lee

Chief Executive Officer

Mr. Shiu Leung Au

Chief Financial Officer (per aggregator; born 1965)

Ms. Millie Yuen Fun Luk

Company Secretary

Directors' Remuneration

ExecutiveTotal remuneration (HKD)Fiscal year

Dr. Stephen Riady

12.53m

FY2023

Mr. John Luen Wai Lee

1.99m

FY2023

Mr. James Siu Lung Lee

1.74m

FY2023

Mr. Brian Riady

0.20m

FY2023

Mr. Davy Kwok Fai Lee

Not publicly disclosed in retrieved sources

—

Board & Management Changes

DateChangeContext

30 Dec 2022

Tsui resigns as INED; Goh appointed INED; Neo becomes Remuneration and Nomination Chair

Board refresh across the Lippo group

7 Jun 2024

John Lee moves from CEO to Deputy Chairman; Davy Lee appointed ED and CEO

Coordinated succession across Lippo, HKC and LCR

31 Mar 2026

Yung's retirement announced

Personal retirement

8 Jun 2026

Yung retires; Tsui re-appointed INED and Audit Committee Chairman

Restores three INEDs, including one with financial expertise

Major Shareholders

HolderShares% of issuedDate

Skyscraper Realty Limited (Lippo Limited group)

445,127,92148.45%

8 Oct 2025

Lippo Capital Limited / Stephen Riady & family

227,427,13524.76%

8 Oct 2025

Mr. Stephen Tai Tak Fung

85,490,8009.30%

31 Mar 2026

Public float (per company, post-distribution)

—26.77%

Sep 2025

Competitive Landscape

Competitors by Segment

SegmentCompetitorListing / ownershipPositioning vs LCRRevenue (latest verified)

Packaged bread (SG/MY)

QAF Limited (Gardenia Singapore; 50% JV Gardenia Bakeries KL)

SGX: Q01

Category leader with far greater scale; announced shifting Gardenia Singapore production to Malaysia

FY2025 revenue S$633.6m (-0.4%)

Packaged bread (SG/MY)

Gardenia Bakeries (KL) Sdn Bhd

50% QAF JV

Malaysian market leader

Not separately verified (included in QAF's S$987m proforma revenue)

Bakery cafés (SG/HK)

BreadTalk Group (incl. Toast Box)

Private (delisted 2020)

Larger multi-brand bakery and café operator

Not publicly disclosed (private)

Bakery cafés (HK)

Maxim's Caterers (Maxim's Cakes, licensed Starbucks HK)

Private

Dominant HK F&B conglomerate

—

Bakery cafés (HK)

Saint Honoré Cake Shop

Private

HK bakery chain

—

Casual dining / QSR (HK)

Café de Coral Holdings

HKEX: 0341

Largest listed HK fast-food group

FY2025/26 (Mar-26) revenue HK$8,183.1m (-4.5%); profit HK$164.1m

Casual dining / QSR (HK)

Fairwood Holdings

HKEX: 0052

HK fast-food peer

FY2025/26 (Mar-26) revenue HK$3,098.8m (flat); profit HK$41.6m

Casual dining (HK)

Tai Hing Group

HKEX: 6811

Cha chaan teng / roast-meat chain

—

Café chains (HK)

Pacific Coffee

Private (China Resources group)

Café competitor

—

Primary healthcare (SG; associate)

Raffles Medical Group, Parkway Shenton (IHH), OneCare, Fullerton Health

Various

Healthway competes in GP and specialist care

—

PE / fund management (associate)

Southeast Asian mid-market PE managers

Various

TIH is small-cap

—

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricLCR (FY2025, Dec)Café de Coral (FY2025/26, Mar)Fairwood (FY2025/26, Mar)QAF (FY2025, Dec)

Revenue

HK$864.5m

HK$8,183.1m

HK$3,098.8m

S$633.6m

Revenue growth

+11.5%-4.5%

~0%

-0.4%

Gross margin

61.5% (cost of sales excludes labour and rent)

9.5%8.7%—

Adjusted EBITDA margin

9.5% (analyst-derived)

7.0% (HK$572.6m)

——

Net margin (attributable)

-7.1%2.0%1.3%—

R&D intensity

Not disclosed (nil)

———

Dividend

Nil

HK$0.40/share (FY total)

—

S$0.04 final (per AR)

“—” = not publicly disclosed.

Recent Developments

--

Company Snapshot

$111M

Revenue

899

Employees

1973

Founded

Queensway, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Manufacturing growth engine. Food-manufacturing revenue rose 25% to HK$436.6m in FY2025 and 21% in H1 2026 [S1][S4].
  • Margin expansion. Gross margin widened from 51.2% (FY2021) to 61.5% (FY2025); adjusted EBITDA rose from -HK$83m to +HK$82m (analyst-derived) [S1][S3].
  • First food-segment profit. HK$16.1m in FY2025 versus a HK$110.7m loss in FY2022 [S1][S3].
  • Deep asset backing. Associates, investments and investment properties carried at ~HK$2.06bn versus ~HK$0.94bn market cap (Jun 2026) [S4][S16].
  • Litigation overhang removed and US$24.75m recovered from insurers [S1][S4].
  • Healthway associate stable. Carrying value HK$505m with sustained revenue growth and expansion via Bridgepoint [S4].

Weaknesses

  • Persistent operating losses. Analyst-derived operating income was -HK$43.7m in FY2025 and has been negative in every year since FY2021 [S1].
  • Heavy overhead. Administrative expenses of HK$436.6m equal 50.5% of revenue [S1].
  • Weakened balance sheet. Net debt rose from HK$205m (FY2021) to HK$718m (FY2025); gearing was 48.1% at Dec 2025 [S1][S3].
  • Earnings quality. FY2025 depended on a HK$104m tax write-back; H1 2026 profit depends on HK$192.6m of non-recurring insurance income [S1][S4].
  • Dividend suspension. No dividend since the HK0.35-cent (pre-consolidation) interim of 2022 [S3].
  • Customer concentration. A single customer accounts for 15.1% of revenue [S1].

Opportunities

  • Capacity addition. The new production line (Q4 2026) should support Malaysian and Singaporean volume growth [S4].
  • Distribution capacity. The Capital Reduction enables future dividends [S1].
  • Property revaluation recovery. H1 2026 brought a +HK$6.0m revaluation; impaired HK offices (HK$120m cumulative impairment) could see reversals [S4].
  • Healthway roll-up. The Bridgepoint acquisition of 16 clinics could lift associate earnings [S4].
  • Portfolio monetisation. Quantedge, GSH and Amasia (Dialpad) holdings total ~HK$186m and could be realised [S4].
  • Interest-cost relief. Lower rates on floating-rate debt (all but HK$7m is floating) [S1].

Threats

  • Hong Kong consumption leakage. Restaurant revenue fell 13% in H1 2026 [S4].
  • Competitor cost moves. QAF's relocation of Gardenia Singapore production to Malaysia [S17].
  • Commodity and energy inflation from the Middle East conflict and Strait of Hormuz disruption [S4].
  • Investee risk. GSH's digital-asset mining pivot raises volatility in a HK$80m holding [S4].
  • Controlled-company risk. The ~73% Riady holding limits minority influence. Related-party loans (HK$132m) and interlocking directorates across Lippo, HKC and LCR raise conflict-of-interest risk [S4][S8].
  • Further impairments on the remaining HK$566.9m of investment properties and JV interests (the FY2025 JV impairment was HK$40.7m) [S1].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar 2025Board meets to approve FY2024 results; FY2024 loss attributable HK$683.7m including HK$386.5m litigation settlement [S1][S24]Trough year; equity down 29%
7 Apr 2025Release of charge over LCR shares held by Skyscraper (74.99%) [S23]Removes encumbrance on control block
H1 2025Capital Reduction proposed: reduce share capital by ~HK$1,554m to HK$150m to address ~HK$636m accumulated losses [S22]Prerequisite for future dividends
May 2025Trading halt; Lippo Limited privatisation and conditional distribution in specie of up to 303,289,730 LCR shares announced; LCR trading resumes 29 May 2025 [S12]Changes LCR shareholder base
23 Jun 2025AGM at Renaissance Harbour View Hotel: accounts adopted, directors re-elected, EY re-appointed, general mandate approved; Chairman absent [S1][S24]CG Code deviation
29 Jul 2025Capital Reduction effective [S1]Distributable reserves restored
28 Aug 2025H1 2025 results: revenue HK$412.1m (+10%); loss attributable HK$80.3m (H1 2024: HK$137.3m); net current liabilities HK$76.6m at 30 Jun 2025 [S6]Narrowing losses; liquidity flag
Aug–Sep 2025Lippo scheme document; IFA and IBC recommend disinterested Lippo shareholders vote in favour; High Court sanctions scheme [S12]Restructuring proceeds
23 Sep 2025Distribution in specie effective; LCR register becomes Skyscraper 48.45%, Lippo Capital 24.76%, public 26.77%; Lippo Limited delisted [S12]Free float rises; direct Riady family holding created
29 Sep 20252025 Interim Report published [S6]Routine
3 Oct 2025Despatch of Lippo scheme cheques and LCR share certificates [S12]Completion
8 Oct 2025Substantial shareholder notices updated [S11]Ownership clarity
FY2025H2G warrants exercised; stake to 28.8% [S1]Clean-energy exposure
FY2025GSH places ~S$112m of new shares and pivots ~S$35m to digital-asset mining [S1]Investee risk profile changes
FY2025HK$104.2m tax over-provision reversed [S1]One-off P&L support
Dec 2025Agreement to purchase a commercial food-manufacturing line [S1]Capacity investment
Feb 2026Insurance agreement: US$24.75m recovery (US$9.9m advanced in 2025) [S1][S4]Half the settlement recouped
~25 Mar 2026Profit warning: FY2025 loss expected at ~HK$60m vs HK$684m [S19]Market pre-alert
31 Mar 2026FY2025 results: revenue HK$864.5m (+11%); loss attributable HK$61.3m; food segment profit HK$16.1m; no dividend [S1]First food-segment profit in five years
31 Mar 2026Announcement that INED Victor Yung will retire at the 2026 AGM [S7]Governance transition
31 Mar 2026Mr. Stephen Tai Tak Fung disclosed at 9.30% [S11]New significant independent shareholder
Apr 20262025 Annual Report (audited; unqualified opinion) delivered [S4]Routine
8 Jun 20262026 AGM; Yung retires; King Fai Tsui appointed INED and Audit Committee Chairman [S4][S18]Board compliance restored
H1 2026H2G becomes an associate after board-nomination right; stake diluted to 22.5% [S4]Accounting reclassification
H1 2026Hong Kong restaurant closures; retail revenue -13% [S4]Retail retrenchment
H1 2026First positive Hong Kong investment-property revaluation (+HK$6.0m) of the period [S4]Property-cycle inflection
Jul 2026Healthway proposes acquisition of Bridgepoint Health (16 primary-care clinics) [S4]Associate growth
Jul 2026H2G completes sale of its biomass-processing subsidiary to focus on LNG [S4]Investee refocus
24 Aug 2026Positive profit alert: H1 2026 profit attributable ~HK$140m [S5]Insurance-driven swing
28 Aug 2026H1 2026 results: revenue HK$434.4m (+5%); profit attributable HK$142.1m; NAV HK$2.2/share; gearing 42.1%; 899 staff; no interim dividend [S4]Balance-sheet repair

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

11 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 648.5 Mn in FY2021 to HKD 864.5 Mn in FY2025.
Lippo China Resources Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue648.5607.4739.4775.3864.5
Cost of sales-316.6-290.9-309.3-300.7-332.6
Gross profit332316.5430.1474.6531.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.